MonoSol Rx, APR expand film formulation development collaboration

MonoSol Rx, the developer of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, and APR Applied Pharma Research s.a. ("APR") announced today an expansion of their relationship to identify and develop film formulations of prescription drug products beyond ondansetron and donepezil to include zolmitriptan. Zolmitriptan is currently commercially available for the acute treatment of migraine headache in adults, and facing initial patent expirations in 2012.

"MonoSol Rx and APR truly understand the value that PharmFilm® offers throughout the pharmaceutical industry," said A. Mark Schobel, president and chief executive officer of MonoSol Rx. "Given our shared expertise, the expansion of this collaboration creates a unique opportunity to broaden the development reach for prescription film products. We look forward to leveraging the capabilities and skills of our partner APR as well as the unique attributes of our PharmFilm® technology to advance several drug targets for film delivery."

MonoSol Rx, along with APR and its partner Labtec GmbH, previously collaborated to develop, commercialize and market ondansetron and donepezil in film. APR, headquartered in Switzerland, is a research and development company focused on the development and licensing of value-added, innovative, selected drug candidates using proprietary and innovative oral and topical delivery systems.

Paolo Galfetti, CEO of APR, remarked, "MonoSol Rx is the clear global leader in pharmaceutical film. We are excited to work together to leverage this drug delivery system to create benefits for patients, physicians and caregivers. Several near-term opportunities exist to transition currently approved drugs to film formulations as a means to improve compliance, differentiation and marketability."


 MonoSol Rx and APR Applied Pharma Research s.a.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the ‘immune self,’ and how can this concept benefit immunological research?